The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S. Human Pharma. His arrival comes at a pivotal time for the company, as Boehringer grows ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

(医药健闻2025年2月21日讯）勃林格殷格翰宣布任命Brian Hilberdink为U.S. Human Pharma总裁。他的到来正值公司的关键时刻，因为勃林格殷格翰正在扩大其现有的产品组合，并加快为推出其管道中的几项新资产做准备。Hilberdink将在培养公司文化和为患者带来有意义的影响方面发挥关键作用。

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.